Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients

References

• Kleinegris MC, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. A systematic review. Thromb Haemost. 2013;110:233–243.
   PubMed Web of Science ®Google Scholar
• Lumsden AB, Rice TW, Chen C, et al. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg. 2007;31:695–704.
   PubMed Web of Science ®Google Scholar
• Shammas NW. Restenosis after lower extremity interventions: current status and future directions. J Endovasc Ther. 2009;1:I170–I182.
   Google Scholar
• Jones DW, Schanzer A, Zhao Y, et al. Growing impact of restenosis on the surgical treatment of peripheral arterial disease. J Am Heart Assoc. 2013;2:e000345.
   PubMed Web of Science ®Google Scholar
• Lichtenberg MK, Carr JG, Golzar JA. Optical coherence tomography: guided therapy of in-stent restenosis for peripheral arterial disease. J Cardiovasc Surg (Torino). 2017;58:518–527.
   PubMed Web of Science ®Google Scholar
• Zhou X, Mou Y, Shen X, et al. The role of atorvastatin on the restenosis process post-PTA in a diabetic rabbit model. BMC Cardiovasc Disord. 2016;16:153.
   PubMed Web of Science ®Google Scholar
• Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.
   PubMed Web of Science ®Google Scholar
• Buccheri D, Piraino D, Andolina G, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8:E1150–E1162.
   PubMed Web of Science ®Google Scholar
• Schillinger M, Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag. 2005;1:73–78.
   PubMedGoogle Scholar
• Zhang B, Yao Y, Sun QF, et al. Circulating mircoRNA-21 as a predictor for vascular restenosis after interventional therapy in patients with lower extremity arterial occlusive disease. Biosci Rep. 2017;37:BSR20160502.
   PubMed Web of Science ®Google Scholar
• Gary T, Prüller F, Raggam R, et al. High residual collagen-induced platelet reactivity predicts development of restenosis in the superficial femoral artery after percutaneous transluminal angioplasty in claudicant patients. Cardiovasc Intervent Radiol. 2016;39:190–194.
   PubMed Web of Science ®Google Scholar
• Anholt RR. Olfactomedin proteins: central players in development and disease. Front Cell Dev Bio. 2014;2:6.
   PubMed Web of Science ®Google Scholar
• Lee JA, Anholt RR, Cole GJ. Olfactomedin-2 mediates development of the anterior central nervous system and head structures in zebrafish. Mech Dev. 2008;125:167–181.
   PubMed Web of Science ®Google Scholar
• Sultana A, Nakaya N, Dong L, et al. Deletion of olfactomedin 2 induces changes in the AMPA receptor complex and impairs visual, olfactory, and motor functions in mice. Exp Neurol. 2014;261:802–811.
   PubMed Web of Science ®Google Scholar
• Shi N, Li CX, Cui XB, et al. Olfactomedin 2 regulates smooth muscle phenotypic modulation and vascular remodeling through mediating runt-related transcription factor 2 binding to serum response factor. Arterioscler Thromb Vasc Biol. 2017;37:446–454.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang D. Advances in endovascular therapy for ischemic cerebrovascular diseases. Chronic Dis Transl Med. 2016;2:135–139.
   PubMedGoogle Scholar
• Singh P, Harper Y, Oliphant CS, et al. Peripheral interventions and antiplatelet therapy: role in current practice. World J Cardiol. 2017;9:583–593.
   PubMed Web of Science ®Google Scholar
• Alraies MC, Darmoch F, Tummala R, et al. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9:640–651.
   PubMed Web of Science ®Google Scholar
• Lunardi M, Zivelonghi C, van den Brink FS, et al. Drug eluting balloon for the treatment of patients with coronary artery disease: current perspectives. Cardiovasc Revasc Med. 2017;pii:S1553-8389:30345-7.
   Web of Science ®Google Scholar
• Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8:382–394.
   PubMed Web of Science ®Google Scholar
• Peeters Weem SM, van Haelst ST, den Ruijter HM, et al. Lack of evidence for dual antiplatelet therapy after endovascular arterial procedures: a meta-analysis. Eur J Vasc Endovasc Surg. 2016;52:253–262.
   PubMed Web of Science ®Google Scholar
• Shi N, Chen SY. From nerve to blood vessel: a new role of Olfm2 in smooth muscle differentiation from human embryonic stem cell-derived mesenchymal cells. J Biomed Res. 2015;29:261–263.
   PubMed Web of Science ®Google Scholar
• Shi N, Guo X, Chen SY. Olfactomedin 2, a novel regulator for transforming growth factor-β-induced smooth muscle differentiation of human embryonic stem cell-derived mesenchymal cells. Mol Biol Cell. 2014;25:4106–4114.
   PubMed Web of Science ®Google Scholar
• Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008;118:1632–1644.
   PubMed Web of Science ®Google Scholar
• Wang K, Wen L, Peng W, et al. Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury. PLoS One. 2014;9:e96894.
   PubMed Web of Science ®Google Scholar
• Beamish JA, He P, Kottke-Marchant K, et al. Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev. 2010;16:467–491.
   PubMed Web of Science ®Google Scholar